According to DataM Intelligence, Metabolic Disorders Therapeutics Market Size was valued at US$74.97 billion in 2024 and is ...

Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned ...

A worldwide, exclusive license is being granted to develop and commercialize enzyme replacement therapies using proprietary platform technology.

Chiesi Group signs agreement with Aliada Therapeutics to advance blood-brain barrier-crossing platform technology in lysosomal storage disorders: Parma, Italy Saturday, November 1 ...

Chiesi has entered an exclusive licence agreement with Aliada to develop ERTs using BBB-crossing technology for LSDs.

Family-controlled Italian biopharma Chiesi Group has entered into an exclusive license agreement with Aliada Therapeutics, a ...

Delhi HC revives rare-disease crowdfunding portal amid low participation, aiming to enhance funding for critical patient treatments.

In its 50th year, JCR Pharmaceuticals, long regarded as one of Japan’s best-kept biotech secrets, is stepping onto the global stage. | Long regarded as one of Japan’s best-kept biotech secrets, JCR ...

Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical ...

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

Robust scale-down agitation models simulate mechanical stress essential for assessing and preventing protein aggregation in ...